Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
HKG: 1801
IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD
China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...
Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Innovent Biologics’ Tafolecimab Shows Strong LDL-C Reduction in Phase III Study
China-based Innovent Biologics, Inc. (HKG: 1801) announced the results of the Phase III CREDIT-1 study...
Innovent’s CLDN18.2 ADC IBI343 Begins Phase I Trial in Australia
Innovent Biologics Inc. (HKG: 1801) has announced the first subject dosing in a Phase I...
Innovent’s Tyvyt Approved for New Gastric Cancer Indication by NMPA
China-based Innovent Biologics, Inc. (HKG: 1801) and its partner Eli Lilly & Co. (NYSE: LLY)...
Innovent’s Parsaclisib Filed for Marketing Approval in China
China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...
Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity
China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...
Innovent’s Cyramza Gains NMPA Approval for Hepatocellular Carcinoma
Innovent Biologics Inc. (HKG: 1801) has announced that the supplementary Biologic License Application (sBLA) for...
Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results
China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...
Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC
China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...
Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO
China-based Innovent Biologics, Inc. (HKG: 1801) presented results of the ORIENT-31 study for its PD-1...
Innovent Biologics Doses First Patient in Higher-Dose Mazdutide Obesity Trial
China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in...
Innovent Biologics’ H1 2022 Revenue Rises 15.3% on Drug Sales Growth
China-based Innovent Biologics, Inc. (HKG: 1801) reported RMB 2.24 billion (USD 326.4 million) in revenue...
Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363
China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...
IASO Biotherapeutics’ BCMA CAR-T Therapy Approved for NMOSD in China
China-based IASO Biotherapeutics announced that the National Medical Products Administration (NMPA) has approved its Investigational...
Innovent Biologics Initiates Phase I Study of IBI311 for Thyroid-Associated Ophthalmopathy
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...
Innovent Biologics’ IBI-112 Achieves Primary Endpoints in Psoriasis Phase II Trial
China-based Innovent Biologics Inc. (HKG: 1801) announced that its interleukin-23 subunit p19 (IL-23p19) monoclonal antibody...
Innovent Biologics Doses First Subject in IBI324 Phase I Study for DME
China-based biotech Innovent Biologics Inc. (HKG: 1801) announced that the first subject has been dosed...